

ANY TUMOR HER2 NEU+

H4613g (HERQLES): A Phase Ib, single-arm, open-label clinical trial to evaluate corrected QT interval & drug-drug interaction of Trastuzumab on Carboplatin in the presence of Docetaxel in patients with HER2-Positive metastatic or locally advanced inoperable cancer

BREAST

Bolero3 CRAD001 W2301: A Randomized Phase III, Double-blind, Placebo-controlled Multi-center Trial of Daily Everolimus in Combination w/ Trastuzumab and Vinorelbine, in Pre-treated Women with HER2/neu Over-expressing Locally Advanced or Metastatic Breast Cancer

BAMC Vaccine Study: A Prospective, Randomized, Single-Blinded, Multi-Center, Phase II Trial of the HER2/neu Peptide GP2 + GM-CSF Vaccine versus GM-CSF Alone in HLA-A2+ OR the Modified HER2/neu Peptide AE37 + GM-CSF Vaccine versus GM-CSF Alone in HLA A2- Node-Positive and High-Risk Node Negative Breast Cancer Patients to Prevent Recurrence

ImClone CP20-0903: An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC 1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy

GENENTECH TDM4997g (TH3RESA): Phase III randomized, multicenter, two-arm, open-label trial to evaluate the efficacy of T-DM1 compared with treatment of physician's choice in patients with HER-2-POSITIVE metastatic breast cancer who have received at least two prior regimens of HER2-DIRECTED therapy

LUNG

ImClone - CP12 0917: A Multi Center Randomized Phase II Study of a Human Anti VEGFR 2 Monoclonal IMC 1121B (Ramucirumab) in Combination with Platinum based Chemotherapy versus Platinum-based Chemotherapy alone as First Line Treatment of Patients with Recurrent or Advanced Non Small Cell Lung Cancer (NSCLC)

BioNumerik DMS32212R: A Randomized, Multicenter, Double-Blind, Phase 3 Trial of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin

LYMPHOMA

Novartis CRAD001N2301: A Randomized, Double Blind, Placebo Controlled, Multicenter, Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients with Diffuse Large B Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response with First Line Rituximab Chemotherapy

Complete Registry: Prospective, Longitudinal, Multinational Registry of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma

OVARIAN

MORAb-003-004PS: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-sensitive Ovarian Cancer in First Relapse

MORAB 003-003PR: A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of MORAb-003 (farletuzumab) in Combination with Paclitaxel Therapy in Subjects with Platinum-Resistant or Refractory Relapsed Ovarian Cancer

AMGEN 20060517 TRINOVA-2: A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin(PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

PANCREATIC

CO-101-001: A Randomized Phase II Trial Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients with Metastatic Pancreatic Cancer

OTSUKA 287-11-201: Phase 2 Placebo-controlled Double-blind Trial of Dasatinib Added to Gemcitabine for Subjects with Locally-advanced Pancreatic Cancer

ENDOMETRIAL

NOVARTIS CBKM120C220: A Phase II, single-arm study of orally administered BKM120 as second-line therapy in patients with advanced endometrial carcinoma

RENAL

IMMATICS IMA901-30: A randomized, controlled Phase III study investigating IMA901 multi-peptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma

Contact:

Lacey Frank, RN BSN, CRC

Director of STOH Clinical Research

Phone: 210-593-5725

Fax: (210) 593-2664

E-mail: lacey.frank@stoh.com

